Odesivimab
| Odesivimab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Odesivimab is a monoclonal antibody used in the treatment of certain viral infections. It is part of a class of medications known as antiviral drugs, specifically designed to target and neutralize specific viral proteins, thereby inhibiting the virus's ability to replicate and cause disease.
Mechanism of Action
Odesivimab functions by binding to a specific epitope on the viral surface protein. This binding prevents the virus from attaching to and entering host cells, which is a critical step in the viral replication cycle. By blocking this interaction, Odesivimab effectively reduces the viral load in the patient's body, allowing the immune system to clear the infection more efficiently.
Clinical Uses
Odesivimab is primarily indicated for the treatment of infections caused by certain strains of viruses, such as respiratory syncytial virus (RSV) and other similar pathogens. It is often used in patients who are at high risk of severe disease, including those with compromised immune systems, the elderly, and infants.
Administration and Dosage
Odesivimab is typically administered via intravenous infusion. The dosage and frequency of administration depend on the patient's weight, the severity of the infection, and the specific viral strain being targeted. Healthcare providers must monitor patients for any adverse reactions during and after the infusion.
Side Effects
Common side effects of Odesivimab include mild infusion-related reactions such as fever, chills, and headache. More serious side effects, although rare, can include hypersensitivity reactions and anaphylaxis. Patients should be monitored closely for any signs of allergic reactions during treatment.
Research and Development
Odesivimab is the result of extensive research into monoclonal antibodies and their potential to treat viral infections. Ongoing studies are exploring its efficacy against emerging viral strains and its potential use in combination with other antiviral therapies.
Regulatory Status
Odesivimab has been approved for use in several countries, with regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) evaluating its safety and efficacy. It is important for healthcare providers to stay informed about the latest guidelines and recommendations regarding its use.
Also see
Drugs for HIV Infection, in the Subclass Antiretroviral Agents
- Fusion Inhibitors (HIV)
- Integrase Inhibitors (HIV)
- Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
- Nucleoside Analogues (HIV)
- Protease Inhibitors (HIV)
HCV NS5A Inhibitors
HCV NS5B Inhibitors (Polymerase inhibitors)
- Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir
Combination Therapies
Drugs for Herpes Virus
- infections (HSV), CMV, others
Acyclovir, Cidofovir, Famciclovir, Foscarnet, Ganciclovir, Valacyclovir, Valganciclovir
Drugs for Influenza
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
